Evidence map›Paper›PMID 38837949›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2024

Advancements and Emerging Therapies in the Medical Management of Uterine Fibroids: A Comprehensive Scoping Review.

Jarosław Krzyżanowski, Tomasz Paszkowski, Piotr Szkodziak, Sławomir Woźniak

Abstract readScoping Review
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Pharmacological treatment for uterine fibroids.The Cochrane database of systematic reviews · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jarosław KrzyżanowskiIII Chair and Department of Gynecology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0002-0018-364X
Tomasz PaszkowskiIII Chair and Department of Gynecology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0002-0256-9853
Piotr SzkodziakIII Chair and Department of Gynecology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0002-3582-067X
Sławomir WoźniakIII Chair and Department of Gynecology, Medical University of Lublin, Lublin, Poland.ORCID 0000-0001-9967-1944

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uterine fibroids, benign tumors originating from uterine smooth muscle cells, vary in prevalence depending on patient ethnicity, hormonal exposure, and genetics. Due to their high incidence, these neoplasms pose a significant burden on healthcare systems. Current treatment strategies range from routine monitoring in asymptomatic cases to surgical procedures such as myomectomy or hysterectomy in symptomatic patients, with an increasing trend toward uterus-preserving or non-surgical alternatives. This review examines the existing medical treatments for uterine fibroids and delves into the potential of emerging therapies. A scoping review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. Medical therapies are divided into hormonal and non-hormonal treatments; however, long-term, safe, and effective treatments in the treatment of uterine fibroids are limited. In addition to established therapies, there is an increasing number of studies investigating the effect of substances such as vitamin D or green tea extract on uterine fibroids. Some studies investigate acupuncture as a possible alternative therapy. While existing treatments offer symptomatic relief and preparation for surgery, our findings point to a significant need for further research into long-term solutions, especially owing to recent limitations in the use of ulipristal acetate due to risk of liver damage. Initial studies involving vitamin D and epigallocatechin gallate are encouraging; however, additional research is required to establish definitive therapeutic roles.

Indexed as

LeiomyomaUterine NeoplasmsAcupuncture TherapyFemaleHumansHysterectomyNorpregnadienesUterine MyomectomyVitamin DNorpregnadienesulipristal acetateVitamin D

Identifiers

PMID38837949
PMCPMC11163935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.